Glenmark to launch DCGI-approved cancer drug in India

Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings, providing Indian patients access to a globally recognized and effective therapy.